Sipuleucel-T [Provenge] prolongs prostate-specific antigen (PSA) doubling time in patients with androgen-dependent prostate cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1564, 2006-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pomegranate juice significantly increases prostate specific antigen (PSA) doubling time in patients with prostate cancer and rising PSA levels

By  

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Sipuleucel-T extends survival in metastatic prostate cancer

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Sipuleucel-T: In Metastatic Castration-Resistant Prostate Cancer

By Plosker Greg L.  

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 101-108

Adis International

Access to resources Recommend Favorite

The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)

By  

Current Radiopharmaceuticals, Vol. 1, Iss. 2, 2008-05 ,pp. : 115-119

Bentham Science Publishers

Access to resources Recommend Favorite

Sipuleucel-T: APC 8015, APC-8015, Prostate Cancer Vaccine – Dendreon

By Adis International Limited  

Drugs in R&D, Vol. 7, Iss. 3, 2006-01 ,pp. : 197-201

Adis International

Access to resources Recommend Favorite